Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;38(11):100884.
doi: 10.1016/j.modpat.2025.100884. Epub 2025 Sep 10.

DNA Methylation-Based Classification of Kidney Neoplasms

Affiliations

DNA Methylation-Based Classification of Kidney Neoplasms

Antonios Papanicolau-Sengos et al. Mod Pathol. 2025 Nov.

Abstract

Renal neoplasms are morphologically and molecularly heterogeneous, with their diagnosis often hindered by interobserver variability and overlapping microscopic features. A subset of cases is unclassifiable despite immunohistochemical, mutation, and cytogenetic-based diagnostic workup. Through examination of the genome-wide DNA methylation signatures of over 2000 renal neoplasms, we identified 23 coherent groups that correlate with known neoplasm types and identified novel clinically relevant subtypes of existing neoplasm types. We used machine learning models to develop and validate a classifier trained on DNA methylation profiles of 1284 samples. The classifier was tested on an external data set of 287 renal neoplasms with >90% concordance between expected neoplasm type and high-score DNA methylation-based classification. Discordance between the original histologic label and methylation class led to potential reclassification of some cases. This work demonstrates proof of principle for the feasibility of a DNA methylation classifier as a clinically useful tool to assist in the diagnosis of renal neoplasms.

Keywords: DNA methylation; epigenome; kidney cancer; machine learning; renal cell carcinoma; tumor classification.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

M.S. is a scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, and a scientific advisor of Arima Genomics, and InnoSIGN, and received research funding from Lilly USA, none related to this study. Other authors declare no competing interests.

References

    1. Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. Nov 2022;82(5):458–468. doi: 10.1016/j.eururo.2022.06.016 - DOI - PubMed
    1. Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. Jan 2015;67(1):85–97. doi: 10.1016/j.eururo.2014.04.029 - DOI - PubMed
    1. Lobo J, Ohashi R, Amin MB, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. Oct 2022;81(4):426–438. doi: 10.1111/his.14700 - DOI - PubMed
    1. Akulenko R, Merl M, Helms V. BEclear: Batch Effect Detection and Adjustment in DNA Methylation Data. PLoS One. 2016;11(8):e0159921. doi: 10.1371/journal.pone.0159921 - DOI - PMC - PubMed
    1. Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. Sep 8 2014;26(3):319–330. doi: 10.1016/j.ccr.2014.07.014 - DOI - PMC - PubMed

Substances

LinkOut - more resources